Cover Image

Biomarkers for sepsis: past, present and future

Giuseppe Chesi, Natale Vazzana, Claudio Giumelli
  • Giuseppe Chesi
    Department of Internal Medicine, C. Magati Hospital, Scandiano (RE), Italy | chesig@ausl.re.it
  • Natale Vazzana
    Department of Internal Medicine, C. Magati Hospital, Scandiano (RE), Italy
  • Claudio Giumelli
    Department of Internal Medicine, C. Magati Hospital, Scandiano (RE), Italy

Abstract

Sepsis is a complication of severe infection associated with high mortality and open diagnostic issues. Treatment strategies are currently limited and essentially based on prompt recognition, aggressive supportive care and early antibiotic treatment. In the last years, extensive antibiotic use has led to selection, propagation and maintenance of drug-resistant microorganisms. In this context, several biomarkers have been proposed for early identification, etiological definition, risk stratification and improving antibiotic stewardship in septic patient care. Among these molecules, only a few have been translated into clinical practice. In this review, we provided an updated overview of established and developing biomarkers for sepsis, focusing our attention on their pathophysiological profile, advantages, limitations, and appropriate evidence-based use in the management of septic patients.

Keywords

Antibiotics; biomarkers; C-reactive protein; procalcitonin; sepsis.

Full Text

PDF
HTML
Submitted: 2016-10-06 16:22:05
Published: 2016-12-15 18:00:24
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
865

Views:
PDF
372
HTML
436

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Giuseppe Chesi, Natale Vazzana, Claudio Giumelli

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185